Moderna's stock surged over 100% following positive Phase 3 results for its personalized mRNA cancer vaccine, developed with Merck. This significant clinical trial success has also notably increased the value of former President Donald Trump's Moderna stock holdings, which he acquired in 2026.
Moderna's stock experienced a massive surge due to the successful Phase 3 trial results for its personalized mRNA cancer vaccine, a significant milestone for mRNA technology in oncology. This news is a major positive catalyst for Moderna, validating its platform and opening up new market opportunities. The filing also highlights that former President Donald Trump, a notable public figure, benefited financially from this surge due to his prior investments in Moderna stock. While his holdings are managed by a blind trust, the disclosure of his gains adds a political dimension to the corporate news. For traders, this presents a clear short-term opportunity in MRNA due to the clinical success and potential long-term implications for mRNA cancer therapies, while also drawing attention to the broader biotech sector.